| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 31.15% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/17/2023 | 31.15% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 08/10/2023 | 63.93% | JP Morgan | $9 → $10 | Maintains | Neutral |
| 07/13/2023 | 63.93% | Morgan Stanley | $10 → $10 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 47.54% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
| 05/11/2023 | 63.93% | Morgan Stanley | $8 → $10 | Maintains | Overweight |
| 01/06/2023 | 31.15% | Morgan Stanley | → $8 | Upgrades | Equal-Weight → Overweight |
| 11/15/2022 | 31.15% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/14/2022 | 31.15% | Cowen & Co. | $10 → $8 | Maintains | Outperform |
| 11/07/2022 | — | Jefferies | Assumes | → Buy | |
| 08/22/2022 | 63.93% | Cowen & Co. | $11 → $10 | Maintains | Outperform |
| 05/10/2022 | 31.15% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/21/2022 | 63.93% | Goldman Sachs | $15 → $10 | Maintains | Neutral |
| 03/17/2022 | 63.93% | UBS | $19 → $10 | Downgrades | Buy → Neutral |
| 12/17/2021 | 63.93% | Morgan Stanley | $15 → $10 | Maintains | Equal-Weight |
| 11/09/2021 | 96.72% | JP Morgan | $24 → $12 | Downgrades | Overweight → Neutral |
| 09/10/2021 | 195.08% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/16/2021 | 162.3% | Morgan Stanley | $36 → $16 | Downgrades | Overweight → Equal-Weight |
| 07/06/2021 | 457.38% | UBS | → $34 | Initiates Coverage On | → Buy |
| 07/06/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/06/2021 | 490.16% | Morgan Stanley | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 490.16% | JP Morgan | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 309.84% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
What is the target price for LifeStance Health Gr (LFST)?
The latest price target for LifeStance Health Gr (NASDAQ: LFST) was reported by Goldman Sachs on November 22, 2023. The analyst firm set a price target for $8.00 expecting LFST to rise to within 12 months (a possible 31.15% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LifeStance Health Gr (LFST)?
The latest analyst rating for LifeStance Health Gr (NASDAQ: LFST) was provided by Goldman Sachs, and LifeStance Health Gr maintained their neutral rating.
When is the next analyst rating going to be posted or updated for LifeStance Health Gr (LFST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeStance Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeStance Health Gr was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating LifeStance Health Gr (LFST) correct?
While ratings are subjective and will change, the latest LifeStance Health Gr (LFST) rating was a maintained with a price target of $9.00 to $8.00. The current price LifeStance Health Gr (LFST) is trading at is $6.10, which is out of the analyst's predicted range.